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Abstract
CD34 and CD38 proteins are usually used as surface markers to identify HSCs and Leukemic stem cells. However, there
have been cases that lacked CD34 or CD38 protein but still had leukemia initiating capacity in B-ALL suggesting the
restrictive of these two markers. CD34 and CD38 expression were detected in most B-ALL and can serve as a specific
biomarker for the prognosis of this subset of leukemia. Lack of CD34 or high CD38 expression is associated with
favorable prognosis.
Background
Acute lymphocytic leukemia (ALL) is the most common
hematological malignancy in childhood and accounts for
about 20% of acute leukemia in adults [1–3]. On the basis
of ontogenic classification, ALL is divided into T-lineage
ALL and B-lineage ALL. B-lineage ALL is characterized
by the expression of the B-cell markers CD19, CD22 and
CD79a [4]. These cells lack expression of CD3 and of
myeloperoxidase. Leukemic cells express various markers
of differentiation that allow the distinction of at least three
main subtypes: Early precursor B-ALL (pro-B-ALL, CD10
−, CD19+, cCD79a+, cCD22+, TdT+), Common B-ALL
(CD10+) and Precursor B-ALL (pre-B-ALL, cytoplasmic
μ+, sIg−, CD10+/−) [5]. Clonal rearrangement analysis of
immunoglobulin genes and TCR has demonstrated the
single-cell origin of ALL. Leukemogenesis is a multistep
process that requires the accumulation of alterations in a
hematopoietic progenitor cell at multiple stages. The
leukemic stem cell (LSC) hypothesis postulates that
leukemia are hierarchically organized and leukemic stem
cells have the capacity to self-renew, give rise to more dif-
ferentiated progeny and maintain the leukemia long-term
[6–8]. CD34+CD38− cells have been shown to be able to
initiate acute myeloid leukemia (AML) [9]. Similarly, pre-
vious studies have reported that in B-ALL, only CD34
+CD38− cells can initiate leukemia in immunodeficient
recipients [10]. Recently, studies have revealed that the
frequency of leukemia-initiating cells (LICs) is high and
consistent between different stages of immunophenotypic
maturation in B-ALL [11, 12]. Therefore, CD34 or CD38
may serve as potential biomarkers of LSCs in B-ALL cells.
CD34 and CD38
CD34 is a cluster-of-differentiation molecule first de-
scribed by Civin et al. in a cell surface glycoprotein [13]
and is encoded by the CD34 gene [14]. Two transcript var-
iants encoding different isoforms have been found for this
gene. The isoform a (b) gene has 2612 (2816) bases, local-
ized on chromosome 1q32. CD34 isoform a (b) protein
has 385 (328) amino acid residues. The CD34 protein
plays a role in the attachment of stem cells to the bone
marrow extracellular matrix or to stromal cells [15, 16].
CD34 is a transmembrane protein that was first identi-
fied on hematopoietic stem and progenitor cells. CD34
is one of the most widely used markers of hematopoietic
stem cells (HSCs) and is involved in the inhibition of
HSC differentiation, HSC expansion, signaling transduc-
tion and anti-adhesion [15].
CD38 is a type II glycoprotein that was originally
described as a lymphoid cell surface differentiation
marker [17]. The CD38 gene has 5694 bases, maps to
chromosome 4p15 and shares a long evolutionary
history with CD157. The CD38 protein has 300 amino
acid residues. CD38 is also a multifunctional ectoenzyme
that catalyzes the synthesis and hydrolysis of cyclic
ADP-ribose (cADPR) from NAD+ to ADP-ribose. These
reaction products are essential for the regulation of
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intracellular Ca2+. CD38 has been used as a prognostic
marker in leukemia [18].
CD34 and CD38 as biomarkers for LICs
The CD34+/CD38− immunophenotype is used to identify
HSCs and LICs in AML [19, 20]. There is an ongoing de-
bate over the existence of LICs in human B-ALL. In 2000,
Cobaleda et al. transplanted Philadelphia chromosome-
positive (Ph+) ALL cells into non-obese diabetic/severe
combined (NOD/SCID) mice and found that only the
CD34+CD38− fraction could give rise to ALL [10]; the
CD34+CD38+ and CD34− fractions contained no cells
with this capability. By adding cytokines, Blair and col-
leagues successfully educated B-ALL cells in serum-free
cell culture. They fractionated the B-ALL cells on the basis
of cell-surface-marker expression and demonstrated that
the ALL cells with long-term proliferative and replating
potential were CD34+CD10−CD19− [21]. Using the new-
born NOD/SCID/IL2Rg (null) xenotransplantation model,
Ishikawa et al. demonstrated that CD38 expression was ir-
relevant in identifying a leukemogenic population in hu-
man primary B-ALL. By intravenously injecting purified
CD34+CD38+CD19+ or CD34+CD38−CD19+ cells from B-
precursor ALL patients, they successfully demonstrated
the leukemia-initiating capacity of both cell types [22]. All
of these studies reached the unanimous verdict that it was
the expression of CD34 that highlighted the LIC popula-
tion, similar to the case of AML. However, Vormoor et al.
and our studies established that blast cells from different
stages of acute lymphoblastic leukemia were all able to re-
constitute the complete leukemia phenotype in vivo, no
matter in which subpopulations they were involved
(CD34, CD38, CD20 or CD19, either positive or negative)
[11, 23]. These conflicting results indicate that key ques-
tions regarding the markers of LSCs in ALL remain
unresolved.
CD34 and CD38 as biomarkers for prognosis in B-ALL
CD34+CD38− B-ALL cells have been used not only in
studies of LSCs, but also in diagnosis and prognosis
(Table 1). In a large cohort of 2028 children with ALL,
the treatment outcomes of a subset of B-lineage ALL
patients with CD10+CD19+CD34+ immature B-
progenitor leukemia were compared with the treat-
ment outcomes of the remaining CD19+ B-lineage
ALL patients. It was found that the CD10+CD19
+CD34+ immature B-progenitor patients were associ-
ated with a more favorable prognosis [24]. In a recent
study of 112 cases of childhood ALL, high propor-
tions of CD34+CD38− cells were positively correlated
with high-risk subgroups and negatively correlated
with outcomes [25]. A study of 63 cases of ALL
found that CD34 protein expression was higher in
pediatric B-ALL than in T-ALL [26]. In another
study, 75 newly diagnosed adult ALL patients were
analyzed for CD34 expression. Expression of this pro-
tein was positively associated with B-cell-lineage ALL.
CD34 was more expressed in poor-risk B-ALL pa-
tients and associated with features of poor prognosis
[27]. Hence, the CD34 expression pattern may have a
prognostic utility in B-ALL.
In contrast to CD34 expression, increased CD38 ex-
pression in acute leukemia (AML or ALL) is associated
with favorable prognosis [18]. In a study of 304 AML
and 138 ALL patients, Ph+ ALL patients showed lower
CD38 expression compared with other cytogenetic
groups [28]. CD38 expression was found to be positively
related to overall survival rates among AML and ALL
patients. Therefore, these studies suggest that higher ex-
pression of CD34 and CD38 may represent prognostic
biomarkers of poor and favorable outcomes for B-ALL,
respectively.
Conclusion
The CD34 and CD38 patterns in B-ALL cannot be
used as specific surface markers to distinguish LSCs
from blast cells. CD34 and CD38 expression are de-
tected in most cases of B-ALL and can serve as spe-
cific biomarkers for prognosis. Lack of CD34 or high
CD38 expression is associated with favorable
prognosis.
Table 1 Summary of the CD34 or CD38 related cell subsets corresponding with B-ALL prognosis
Cell Subset Prognosis Reference
CD34 + positive/negative CD34 expression is favorable and significant prognosis in childhood B-lineage ALL
(age 1 to 10 years). [26]
CD34 mostly expressed in poor risk adult B-ALLs patients, characterized with higher WBC
cell count, and higher percentage of peripheral blood leukemic cells [27]
CD38 + positive Ph + ALL showed lower CD38 expression than Ph- groups. Overall survival favored ALL
patients with higher CD38 levels [26]
CD34 + CD38− cells negative A high proportion of CD34+/CD38- cells is associated with clinical and biological features
and a poor prognosis of childhood ALL. [25]
CD10 + CD19 + CD34+ positive With CD10 + CD19’CD34+ immature B-progenitor subset, pediatric B-lineage ALL patients
may have favorable characteristics to achieve favorable EFS outcomes. [24]
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